A meeting of the U.S. FDA's Antimicrobial Drugs Advisory Committee is scheduled for June 8, 2023, to discuss the biologics license application (BLA) for nirsevimab (Beyfortus®), a long-acting respiratory syncytial virus (RSV) F protein inhibitor, single dose monoclonal antibody (mAbs).
Will U.S. FDA Approve New RSV Immunization for Infants
A meeting of the U.S. FDA's Antimicrobial Drugs Advisory Committee is scheduled for June 8, 2023, to discuss the biologics license application (BLA) for nirsevimab (Beyfortus®), a long-acting respiratory syncytial virus (RSV) F protein inhibitor, single dose monoclonal antibody (mAbs).
Will the FDA Approve the New RSV Monoclonal Antibody for Infants
A meeting of the U.S. FDA's Antimicrobial Drugs Advisory Committee is scheduled for June 8, 2023, to discuss the biologics license application (BLA) for nirsevimab (Beyfortus®), a long-acting respiratory syncytial virus (RSV) F protein inhibitor, single dose monoclonal antibody (mAbs).
Will the FDA Approved the New RSV Monoclonal Antibody for Infants
A meeting of the U.S. FDA's Antimicrobial Drugs Advisory Committee is scheduled for June 8, 2023, to discuss the biologics license application (BLA) for nirsevimab (Beyfortus®), a long-acting respiratory syncytial virus (RSV) F protein inhibitor, single dose monoclonal antibody (mAbs).
Japan's Mpox Outbreak Was Connected with International Travel
The Lancet recently published a Correspondence that concluded the continuous reporting of new mpox cases in Japan suggests that ongoing local transmission of the sexually transmitted virus might be occurring.
The first imported mpox case in Japan was reported on July 25, 2022, and patients have been sporadically reported since then, mainly with a history of international travel or after having been in contact with travelers.
In Japan, 8 mpox cases were reported in 2022.
Flu Season Migrates South
The World Health Organization (WHO) recently published Influenza Update N° 446, which reported influenza detections decreased further in 2023 due to a decline in detections in the northern hemisphere.
While some countries in the southern hemisphere reported an increase in influenza detections in recent weeks.
Furthermore, in the temperate zones of the southern hemisphere, influenza activity remained low. However, influenza activity increased in Australia, Chile, and Severe acute respiratory illness cases in New Zealand.
England's Sexually Transmitted Disease Outbreaks Set Records
New data announced today by the UK Health Security Agency (UKHSA) indicates record levels of chlamydia, gonorrhea, and syphilis were diagnosed in England during 2022.
Published on June 6, 2023, this new UKHSA report analyzes the 400 sexually transmitted infections (STIs) diagnoses made daily in 2022.
The latest data shows gonorrhea diagnoses totaled 82,592 in 2022, an increase of 50.3% in one year. This is the most significant number of gonorrhea diagnoses in any one year since 1918.
Global Certificate System Launches in June 2023
The World Health Organization (WHO) and European Commission (EC) today announced a digital health partnership launching in June 2023.
Confirmed on June 5, 2023, the WHO will take up the European Union (EU) digital COVID-19 certification process to establish a global system that will help facilitate worldwide mobility and protect people from ongoing and future health threats, including pandemics.
2019 to 2020 Saw Decrease in Pediatric Emergency Visit Rate
Decrease seen in emergency department visit rates from 2019 to 2020 for both sexes and across races/ethnicities
Nirmatrelvir-Ritonavir Effective for Outpatient Treatment of COVID-19
Reduces 30-day risk for hospitalization and death, while only death was reduced in association with molnupiravir